Target Corporation vs State Street SPDR S&P Biotech ETF — how do they compare? Target Corporation trades at $138.64 (market cap $63.40B), while State Street SPDR S&P Biotech ETF trades at $154.49. The key difference: Target Corporation pays a 3.32% dividend while State Street SPDR S&P Biotech ETF pays none. Which is the better fit depends on your goals.
| TGT | XBI | |
|---|---|---|
Market Cap | $63.40B | — |
Sector | Consumer Cyclical | Broad Market / Factor |
52-Week High | $141.19 | $164.28 |
52-Week Low | $83.68 | $85.16 |
Enterprise Value | $78.70B | — |
Dividend Yield | 3.32% | — |
Trailing returns across standard periods
Latest headlines on both assets
With 1,926 stores (as of the end of fiscal 2021), Target is a leading American general merchandise retailer, offering a variety of products across several categories, including beauty and household essentials (26% of fiscal 2021 sales), food and beverage (19%), home furnishings and décor (19%), hardlines (18%), and apparel and accessories (17%). Most of Target's stores are large, averaging more than 125,000 square feet. The company has a significant e-commerce presence, deriving around 19% of sales from the channel (up from about 9% in fiscal 2019, before the pandemic). In addition to its namesake stores, Target owns Shipt, an online same-day delivery platform. After it exited Canada in 2015, virtually all of Target's revenue is generated from the United States.
Read more on TGT →XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →